SCHEMBL4966313

SCHEMBL4966313

CC(C)[C@H](CO)NC(=O)C1(c2ccc(Cl)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 2/20 0.48
AVPR1A P37288 8/20 0.47
KCNH2 Q12809 1/20 0.45
HSD11B1 P28845 3/20 0.44
GAA P10253 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44
LMNA P02545 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
OXTR P30559 1/20 0.42
CCR1 P32246 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6406749 0.81 AVPR1A (0.48) HDAC4SMN1; SMN2ALDH1A1AVPR1AKCNH2
SCHEMBL6405946 0.81 AVPR1A (0.48) HDAC4SMN1; SMN2ALDH1A1AVPR1AKCNH2
SCHEMBL6406287 0.81 HDAC4 (0.44) HDAC4SMN1; SMN2ALDH1A1AVPR1AKCNH2
SCHEMBL6406294 0.81 HDAC4 (0.44) HDAC4SMN1; SMN2ALDH1A1AVPR1AKCNH2
SCHEMBL5049115 0.79 AVPR1A (0.57) HDAC4SMN1; SMN2ALDH1A1AVPR1AKCNH2
SCHEMBL6405987 0.78 AVPR1A (0.53) HDAC4SMN1; SMN2ALDH1A1AVPR1AKCNH2
SCHEMBL4971409 0.76 HDAC4 (0.47) HDAC4SMN1; SMN2ALDH1A1AVPR1AKCNH2
SCHEMBL6410915 0.75 ALDH1A1 (0.62) HDAC4SMN1; SMN2ALDH1A1AVPR1AKCNH2
SCHEMBL6404844 0.75 ALDH1A1 (0.62) HDAC4SMN1; SMN2ALDH1A1AVPR1AKCNH2
SCHEMBL6405064 0.74 AVPR1A (0.49) HDAC4SMN1; SMN2ALDH1A1AVPR1AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773780-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP claimed
EP-1773780-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP claimed
WO-2006012227-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO claimed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US claimed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288338-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HDAC4 1710/4885SMN1; SMN2 3497/4885ALDH1A1 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.